Stockreport

Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update

Compass Therapeutics, Inc.  (CMPX) 
PDF In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% over [Read more]